mRNA Technology - Search News

FDA, RNA and flu vaccine

FDA won’t consider a new mRNA vaccine for flu despite the technology’s life-saving promise

The U.S. Food and Drug Administration is refusing to consider a new mRNA flu vaccine made by Moderna, the company revealed in a statement on Tuesday.

· 16h

Moderna’s mRNA Flu Vaccine Back Under FDA Review

· 1d

FDA reverses course, will review Moderna's mRNA flu vaccine

· 1d

FDA reverses course on Moderna's flu vaccine

The FDA says it will now review a new m-r-n-a flu vaccine from Moderna.

· 1d

FDA reverses course and will review Moderna’s mRNA flu shot, company says

· 1d

FDA plans review of Moderna flu vaccine for older adults

· 1d

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

The FDA news is largely positive for MRNA stock as it positions the company’s influenza vaccine for the upcoming flu season.

· 1d

FDA reverses course, agrees to review Moderna's flu vaccine

· 1d

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

Morning Overview on MSN

New mRNA flu shot proves 30%+ more powerful at stopping influenza A

Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy against influenza A than a licensed egg-based flu shot in a large Phase 3 trial enrolling 40,

BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.